Cinacalcet Hydrochloride(sin ah kal’ set)
SensiparDNC
PREGNANCY CATEGORY C
Drug Classes
Calcimimetic
Calcium-lowering drug
Therapeutic Actions
Increases the sensitivity to extracellular calcium of the calcium-sensing receptors on the surface of the chief cell of the parathyroid gland, resulting in a decrease in parathyroid hormone secretion. The drop in parathyroid hormone level leads to a decrease in serum calcium levels.
Indications
Secondary hyperparathyroidism in patients receiving dialysis for chronic renal disease
Treatment of hypercalcemia in patients with parathyroid carcinoma
Treatment of severe hypercalcemia in patients with primary hyperparathyroidism unable to have parathyroidectomy.
Contraindications and Cautions
Contraindicated with allergy to any component of the drug, lactation, hypocalcemia.
Use cautiously with a history of seizure disorders, moderate to severe hepatic impairment, pregnancy.
Available Forms
TabletsDNC—30, 60, 90 mg
Dosages
Adults
Secondary hyperparathyroidism: 30 mg/day PO; monitor serum calcium and phosphorous levels within 1 wk after starting therapy and intact parathyroid hormone levels within 1–4 wk of starting therapy to adjust dosage to therapeutic level. May increase dose 30 mg every 2–4 wk to a maximum dose of 180 mg/day. Titrate to target intact parathyroid hormone levels of 150–300 pg/mL. May be combined with vitamin D and phosphate binders.
Hypercalcemia associated with parathyroid carcinoma or severe hypercalcemia in patients with primary hyperparathyroidism: Initially, 30 mg PO bid to maintain calcium levels within a normal range; may adjust dosage every 2–4 wk in sequential dosages of 60 mg bid, then 90 mg bid to a maximum dosage of 90 mg tid to qid.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
